Multimodal (EEG-fMRI) functional connectivity study of levodopa effect in Parkinson’s disease

Aim: To assess if the intake of levodopa in patients with Parkinson’s Disease (PD) changes cerebral connectivity, as revealed by simultaneous recording of hemodynamic (functional MRI, or fMRI) and electric (electroencephalogram, EEG) signals. Particularly, we hypothesize that the strongest changes in FC will involve the motor network, which is the most impaired in PD. Methods: Eight patients with diagnosis of PD “probable”, therapy with levodopa exclusively, normal cognitive and affective status, were included. Exclusion criteria were: moderate-severe rest tremor, levodopa induced dyskinesia, evidence of gray or white matter abnormalities on structural MRI. Scalp EEG (64 channels) were acquired inside the scanner (1.5 Tesla) before and after the intake of levodopa. fMRI functional connectivity was computed from four regions of interest: right and left supplementary motor area (SMA) and right and left precentral gyrus (primary motor cortex). Weighted partial directed coherence (w-PDC) was computed in the inverse space after the removal of EEG gradient and cardioballistic artifacts. Results and discussion: fMRI group analysis shows that the intake of levodopa increases hemodynamic functional connectivity among the SMAs / primary motor cortex and: sensory-motor network itself, attention network and default mode network. w-PDC analysis shows that EEG connectivity among regions of the motor network has the tendency to decrease after the intake the levodopa; furthermore, regions belonging to the DMN have the tendency to increase their outflow toward the rest of the brain. These findings, even if in a small sample of patients, suggest that other resting state physiological functional networks, beyond the motor one, are affected in patients with PD. The behavioral and cognitive tasks corresponding to the affected networks could benefit from the intake of levodopa.

Fractal descriptors for quantifying brain complexity in MRI

Magnetic Resonance Imaging (MRI) is the in vivo technique most commonly employed to characterize changes in brain structures. The conventional MRI-derived morphological indices are able to capture only partial aspects of brain structural complexity. Fractal geometry and its most popular index, the fractal dimension (FD), can characterize self-similar structures including grey matter (GM) and white matter (WM). Previous literature shows the need for a definition of the so-called fractal scaling window, within which each structure manifests self-similarity. This justifies the existence of fractal properties and confirms Mandelbrot’s assertion that "fractals are not a panacea; they are not everywhere". In this work, we propose a new approach to automatically determine the fractal scaling window, computing two new fractal descriptors, i.e., the minimal and maximal fractal scales (mfs and Mfs). Our method was implemented in a software package, validated on phantoms and applied on large datasets of structural MR images. We demonstrated that the FD is a useful marker of morphological complexity changes that occurred during brain development and aging and, using ultra-high magnetic field (7T) examinations, we showed that the cerebral GM has fractal properties also below the spatial scale of 1 mm. We applied our methodology in two neurological diseases. We observed the reduction of the brain structural complexity in SCA2 patients and, using a machine learning approach, proved that the cerebral WM FD is a consistent feature in predicting cognitive decline in patients with small vessel disease and mild cognitive impairment. Finally, we showed that the FD of the WM skeletons derived from diffusion MRI provides complementary information to those obtained from the FD of the WM general structure in T1-weighted images. In conclusion, the fractal descriptors of structural brain complexity are candidate biomarkers to detect subtle morphological changes during development, aging and in neurological diseases.